Houchingue Eghbali

5.7k total citations
89 papers, 1.9k citations indexed

About

Houchingue Eghbali is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Houchingue Eghbali has authored 89 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pathology and Forensic Medicine, 38 papers in Oncology and 24 papers in Genetics. Recurrent topics in Houchingue Eghbali's work include Lymphoma Diagnosis and Treatment (62 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Lung Cancer Treatments and Mutations (22 papers). Houchingue Eghbali is often cited by papers focused on Lymphoma Diagnosis and Treatment (62 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Lung Cancer Treatments and Mutations (22 papers). Houchingue Eghbali collaborates with scholars based in France, Netherlands and Belgium. Houchingue Eghbali's co-authors include B Hœrni, Pierre Soubeyran, Patrice Carde, M. Henry‐Amar, F. Bonichon, John Raemaekers, Pierre Richaud, José Thomas, Evert M. Noordijk and M Trojani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Houchingue Eghbali

84 papers receiving 1.8k citations

Peers

Houchingue Eghbali
B. Vaughan Hudson United Kingdom
Woodrow Wells Canada
Agustín Avilés Mexico
Massimo Magagnoli Italy
Max Wolf Australia
Maura Brugiatelli Italy
R. Somers Netherlands
G P Canellos United States
P Grozea United States
R S Cox United States
B. Vaughan Hudson United Kingdom
Houchingue Eghbali
Citations per year, relative to Houchingue Eghbali Houchingue Eghbali (= 1×) peers B. Vaughan Hudson

Countries citing papers authored by Houchingue Eghbali

Since Specialization
Citations

This map shows the geographic impact of Houchingue Eghbali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Houchingue Eghbali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Houchingue Eghbali more than expected).

Fields of papers citing papers by Houchingue Eghbali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Houchingue Eghbali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Houchingue Eghbali. The network helps show where Houchingue Eghbali may publish in the future.

Co-authorship network of co-authors of Houchingue Eghbali

This figure shows the co-authorship network connecting the top 25 collaborators of Houchingue Eghbali. A scholar is included among the top collaborators of Houchingue Eghbali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Houchingue Eghbali. Houchingue Eghbali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eghbali, Houchingue & Aline Papaxanthos-Roche. (2010). The impact of lymphoma and treatment on male fertility. Expert Review of Hematology. 3(6). 775–788. 4 indexed citations
2.
Kaaij, Marleen A. E. van der, Natacha Heutte, Jannie van Echten‐Arends, et al.. (2009). Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica. 94(12). 1691–1697. 49 indexed citations
3.
Cazin, Bruno, Marine Diviné, Stéphane Leprêtre, et al.. (2008). High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. British Journal of Haematology. 143(1). 54–59. 13 indexed citations
4.
Noordijk, Evert M., Patrice Carde, N. Dupouy, et al.. (2006). Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. Journal of Clinical Oncology. 24(19). 3128–3135. 149 indexed citations
5.
6.
Eghbali, Houchingue, et al.. (2005). The EORTC strategy in the treatment of Hodgkin's lymphoma. European Journal Of Haematology. 75(s66). 135–140. 43 indexed citations
7.
Soubeyran, Pierre, Alain Monnereau, Houchingue Eghbali, et al.. (2005). Fludarabine phosphate–CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: A dose-finding study. European Journal of Cancer. 41(17). 2630–2636.
8.
Eghbali, Houchingue, et al.. (2002). Actualités des lymphomes. Bulletin du Cancer. 89(1). 89–99.
9.
Aleman, Berthe M.P., M. Henry‐Amar, Umberto Tirelli, et al.. (2001). Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884. Blood. 98(11). 6 indexed citations
10.
Rizzoli, R., D. Thiébaud, Nigel Bundred, et al.. (1999). Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3545–3550. 32 indexed citations
11.
Flechtner, Hans‐Henning, Jens Ulrich Rüffer, M. Henry‐Amar, et al.. (1998). Quality of life assessment in Hodgkin’s disease: A new comprehensive approach. Annals of Oncology. 9. s147–s154. 27 indexed citations
12.
Mathoulin‐Pélissier, Simone, et al.. (1998). Faisabilité d'un suivi de patients transfusés. Transfusion Clinique et Biologique. 5(4). 266–274. 12 indexed citations
13.
14.
Richaud, Pierre, Pierre Soubeyran, Houchingue Eghbali, et al.. (1998). Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: Results of a pilot study. International Journal of Radiation Oncology*Biology*Physics. 40(2). 387–390. 55 indexed citations
15.
Soubeyran, Pierre, Houchingue Eghbali, M Trojani, et al.. (1996). Is there any place for a wait-and-see policy in stage I0 follicular lymphoma?. Annals of Oncology. 7(7). 713–718. 37 indexed citations
16.
Soubeyran, Pierre, Houchingue Eghbali, F. Bonichon, et al.. (1991). Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. European Journal of Cancer and Clinical Oncology. 27(12). 1606–1613. 50 indexed citations
17.
Bonichon, F., et al.. (1989). Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. British Journal of Cancer. 59(4). 645–649. 17 indexed citations
18.
Hœrni, B, R Zittoun, Alain Audebert, et al.. (1986). [Data collection from patients treated for Hodgkin's disease. Relation to quality of life].. PubMed. 73(3). 305–10. 1 indexed citations
19.
Hœrni, B, et al.. (1983). Qualité de vie pendant et après association radio-chimiothérapique pour maladie de Hodgkin. Appréciation de 60 malades.. Bulletin du Cancer. 70(4). 2 indexed citations
20.
Eghbali, Houchingue, et al.. (1978). Hodgkin's disease treated by chemotherapy and large field irradiation. 17(4). 289–295. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Vaughan Hudson Breakdown of academic impact, for papers by Woodrow Wells Breakdown of academic impact, for papers by Agustín Avilés Breakdown of academic impact, for papers by Massimo Magagnoli Breakdown of academic impact, for papers by Max Wolf Breakdown of academic impact, for papers by Maura Brugiatelli Breakdown of academic impact, for papers by R. Somers Breakdown of academic impact, for papers by G P Canellos Breakdown of academic impact, for papers by P Grozea Breakdown of academic impact, for papers by R S Cox
Rankless by CCL
2026